Opexa Therapeutics Inc. (OPXA) Releases Earnings Results, Misses Expectations By $0.03 EPS
Opexa Therapeutics Inc. (NASDAQ:OPXA) released its earnings results on Monday. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.03. Opexa Therapeutics had a negative return on equity of 109.48% and a negative net margin of 324.97%.
Opexa Therapeutics (NASDAQ:OPXA) opened at 0.5601 on Tuesday. The firm’s market capitalization is $3.95 million. The firm has a 50-day moving average price of $2.56 and a 200-day moving average price of $3.36. Opexa Therapeutics has a one year low of $0.50 and a one year high of $5.10.
An institutional investor recently raised its position in Opexa Therapeutics stock. Vanguard Group Inc. raised its position in shares of Opexa Therapeutics Inc. (NASDAQ:OPXA) by 5.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 164,354 shares of the biopharmaceutical company’s stock after buying an additional 8,649 shares during the period. Vanguard Group Inc. owned approximately 2.35% of Opexa Therapeutics worth $679,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.40% of the company’s stock.
A number of equities research analysts recently commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Opexa Therapeutics in a report on Sunday, August 14th. Aegis downgraded Opexa Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 28th. Zacks Investment Research downgraded Opexa Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 26th. Finally, Maxim Group reissued a “buy” rating and issued a $18.00 price target on shares of Opexa Therapeutics in a report on Friday, August 12th.
Opexa Therapeutics Company Profile
Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.
Receive News & Stock Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related stocks with our FREE daily email newsletter.